Estrogen-receptor negative (ERneg) breast cancer is an aggressive breast cancer subtype in 27 the need for new therapeutic options. We have analyzed metabolomics, proteomics and 28 transcriptomics data for a cohort of 276 breast tumors (MetaCancer study) and nine public 29 transcriptomics datasets using univariate statistics, meta-analysis, Reactome pathway analysis, 30 biochemical network mapping and text mining of metabolic genes. In the MetaCancer cohort, a 31 total of 29% metabolites, 21% proteins and 33% transcripts were significantly different (raw p < 32 0.05) between ERneg and ERpos breast tumors. In the nine public transcriptomics datasets, on 33 average 23% of all genes were significantly different (raw p < 0.05). Specifically, up to 60% of 34 the metabolic genes were significantly different (meta-analysis raw p < 0.05) across the 35 transcriptomics datasets. Reactome pathway analysis of all omics showed that energy 36 metabolism, and biosynthesis of nucleotides, amino acids, and lipids were associated with 37 ERneg status. Text mining revealed that several significant metabolic genes and enzymes have 38 been rarely reported to date, including PFKP, GART, PLOD1, ASS1, NUDT12, FAR1, PDE7A, 39 FAHD1, ITPK1, SORD, HACD3, CDS2 and PDSS1. Metabolic processes associated with 40 ERneg tumors were identified by multi-omics integration analysis of metabolomics, proteomics 41 and transcriptomics data. Overall results suggested that TCA anaplerosis, proline biosynthesis, 42 synthesis of complex lipids and mechanisms for recycling substrates were activated in ERneg 43 tumors. Under-reported genes were revealed by text mining which may serve as novel 44 candidates for drug targets in cancer therapies. The workflow presented here can also be used 45 for other tumor types. 46 47
Introduction 50
Estrogen receptor signaling is one of the main molecular features that determines the 51 aggressiveness and the clinical course of breast cancer. Estrogen receptor negative breast 52 tumors are aggressive and have a poor prognosis due to their high proliferation rate and their 53 resistance to many therapeutic approaches.
The estrogen-independent growth of ERneg 54 tumors depends on a range of biological pathways, including central energy and nucleotide 55 metabolism 33, 38 , motivating to characterize metabolic dysregulations associated with the 56 aggressive tumor phenotype. Human metabolic network's operation and regulation is governed 57 by up to 10% genes in the human genome. Many of these genes and associated pathways are 58 dysregulated and fuel a tumor's growth, therefore they are potential drug targets. 59
How to identify these dysregulations in aggressive breast tumors and rank them? One of the 60 experimental approaches is to analyze the tumors with omics assays including metabolomics, 61 proteomics and transcriptomics. In fact, breast tumors are extensively analyzed using these 62 assays 1, 11, 17, 18, 22, 24, 25, 27, 29, 32, 39 . Tumor metabolomics reveals new insights into breast cancer 63 metabolism 6, 8, 31, 44 MetaCancer consortium has been built to identify and validate new breast 64 cancer biomarkers based on metabolomics 6, 7 . We have previously shown that beta-alanine and 65 glutamate to glutamine ratio (GGR) are associated with aggressive phenotype in the 66 MetaCancer cohort 6, 7 . Furthermore, a multi-omics approach has been successfully used to 67 characterize metabolic dysregulation and identify potential new therapeutic targets in lung 68 cancer 13 , but such investigations are limited for breast tumors. These approaches yield 69 different lists of potential targets, creating a challenge to identify which genes and pathways can 70 be targeted in follow-up experiments. A handful of genes are over-studied in reference to tumor 71 biology, for example IDH1 or FH, indicating a selection bias. However, poorly-studied significant 72 genes and associated metabolic pathways provide an additional repertoire to identify new drug 73 targets beyond the handful of genes. 74
75
In the present study, we integrated tissue-based metabolomics with proteomics and 76 transcriptomics in the MetaCancer cohort to identify the metabolites, proteins and metabolic 77 genes that are associated with ERneg phenotype. To identify metabolic genes that were poorly 78 studied in ERneg tumors, we performed Gene Expression Omnibus (GEO) based meta-analysis 79 of nine publicly available datasets, and ranked the metabolic genes based on their significance 80 in meta-analysis and literature count. 81
82
Results 83 Workflow to prioritize tumor metabolic genes 84
We applied a new bioinformatics workflow ( Figure 1 ) to characterize metabolic dysregulations 85 between ERpos and ERneg breast tumors. We used metabolite, protein and transcript 86 measurements data from the MetaCancer cohort 6, 7 in addition to publicly available gene 87 expression data (Table S1 ). The workflow incorporates significance testing, gene expression 88 meta-analysis, pathway analysis, network mapping and text mining. The output of this workflow 89 yields lists of metabolic pathways and under-studied metabolic genes, here associated with 90
ERneg breast tumor biology. 91 92
Molecular differences between ERneg and ERpos breast tumors 93
Table 1 summarizes significantly different transcripts, proteins and metabolites between ERneg 94 and ERpos tumors in the MetaCancer and the public datasets. We used raw p-values to 95 interpret the molecular differences across all multi-omics levels of cellular regulation using 96 bioinformatics approaches. Hence, we did not correct p-values for multiple hypothesis testing 97 because our objective was not to find a diagnosis biomarker panel that can distinct the tumor 98 subtypes. 99 100 MetaCancer dataset: The metabolomics data of the MetaCancer study consisted of 470 101 metabolites detected by gas chromatography/time of flight mass spectrometry, including 161 102 identified metabolites and 309 unidentified metabolites. Breast tumors from 251 women were 103 studied, of which 192 were ERpos and 59 were ERneg. A total of 164 metabolites (63 identified 104 and 101 unidentified metabolites) were significantly different between ERpos and ERneg cancer 105 groups (raw p-value < 0.05) with and average effect size of 1.37-fold changes, ranging from 106 0.59-3.03-fold. The levels of 133 metabolites were higher in ERneg tumors and 31 metabolites 107 were lower in ERneg tumors ( Figure 2C , Table S4 ). 108
The proteomics MetaCancer data consisted of 125 formalin-fixed paraffin embedded 109 (FFPE) samples using 96 ERpos tumors and 29 ERneg tumors. FFPE samples were not 110 available for all 251 patients. ER status for one sample was not known. We could not use the 111 exact same fresh frozen tumors as used for the metabolomics analysis because of limited 112 sample availability. Conversely, FFPE samples are not useful for metabolomics analysis due to 113 the FFPE fixation process. Out of total 1500 detected proteins, 1231 were found in at least six 114 samples in either ERpos or ERneg groups and were kept in the dataset for statistics analysis 115 (Table S5) . A total 295 proteins were found to be significantly different regulated (raw p-value < 116 0.05) using the Mann-Whitney U test. The levels of 97 proteins were lower in ERneg tumors and 117 198 proteins were higher in ERneg tumors ( Figure 2B , Table S5 ). 118
The transcriptomics MetaCancer dataset was downloaded from the gene expression 119 omnibus (GEO) database with accession number GEO59198. The data set included 18401 120 genes determined in 122 ERpos and 32 ERneg breast tumors (Table 1 ). A total of 6040 genes 121 (33%) were significantly different (raw p-value < 0.05) between ERpos and ERneg groups using 122 the GEO2R utility (27008011). Among those genes, 3103 were under-expressed and 2937 were 123 over-expressed in the ERneg tumors (Table1 , Table S6 ). We have then utilized the Expasy 124 database to obtain enzyme commission (EC) annotations for all human genes from NCBI. We 125 selected the EC numbers that chemically transform small-molecules by excluding enzymes that 126 use proteins or genes as substrates, yielding a total of 1549 human genes coding for metabolic 127 enzymes (Table S7 ). 540 metabolic genes (35%) were found to be significantly different (raw p-128 value < 0.05) in ERneg tumors compared to ERpos tumors in the MetaCancer cohort ( Figure  129 2A, Table S7 and Figure S1 ). 130 131 Breast tumor public gene expression datasets: We collected eight additional gene 132 expression datasets for which the ER status was known. The eight additional GEO studies 133 consisted of total 540 for ERpos and 299 ERneg breast cancer samples, ranging between 32-134 138 samples for ERpos tumors and 10-88 ERneg tumors (Table 1) . On average, we found 23% 135 of all transcripts to be significantly different expressed between ERpos and ERneg, ranging from 136 5-42% ( Figure 2E ). Similar to the MetaCancer study, 47% of all significant genes were over-137 expressed, 53% were under-expressed. A meta-analysis by comparing the raw p-values 138 distribution of each gene with across all datasets with a null-distribution using the Smirnov test (KS) yielded a total of 929 metabolic genes which were significant (raw p-value 140 <0.05) ( Figure 2F , Table S7 , Figure S1 ). Estrogen receptor 1 (ESR1) gene expression was 141 lower in ERneg tumors across all gene expression datasets (Table S6) . 142 143
Integrated pathway analysis and visualization 144
Next, we investigated whether these different omics data can be grouped by functional 145 relationships. Here, we focused on integrated analysis of metabolic pathways. We used 146 statistical over-representation as generic tool to summarize and rank the differential regulation 147 of genes, proteins and metabolites by mapping to the Reactome database 12 . We used 148
Reactome as reference database because it uses GO terms and because it provides more 149 comprehensive mapping of genes to metabolic pathways than KEGG pathways, BioCyc or 150 HMDB. We then confined the Reactome analysis to significantly regulated molecular markers, 151 yielding a joint list of 542 genes, 104 proteins and 56 metabolites. Notably, 20 metabolites, 7 152 proteins and 45 genes could not be mapped to any pathway set and therefore had to be 153 discarded from further analysis. The lists of remaining molecular markers were summarized by 154
Reactome overrepresentation analysis into 886 pathways (Table S9 ) of which 88 (~10%) were 155 found to be significantly enriched ( Figure 3 ). Interestingly, for most pathways, the over-156 representation analysis was based on all three omics levels, while 15 pathways were supported 157 by only protein and gene lists and 8 pathways were based solely on gene set enrichments. This 158 finding is based on the larger size of gene lists compared to proteins or metabolites, in addition 159 to bias in proteomics and metabolomics data acquisitions. For example, the metabolomics 160 platform used here did not cover biosynthesis of complex lipids, while our FFPE-based 161 proteomics method failed to observed low-abundant proteins. We did not use lipidomics 162 analysis here because most lipids are not annotated by specific enzymes in Reactome. (Table S9) . Key specific pathways are within these branches were 170 glycolysis, pentose phosphate pathway, TCA cycle, nucleotide salvage, glutathione conjugation, 171 steroids metabolism, fatty acyl-CoA biosynthesis, serine biosynthesis and metabolism of 172 aromatic amino acids. These pathways were also found to be significantly associated with 173
ERneg phenotype when genes, protein and metabolite lists were analyzed separately ( Table  174 S10-S13). Several branches indicate the importance of lipids, nucleotides and amino acids for (also see Figure S2 , Table S2 ). For example, an increase in nucleotide metabolism is 185 substantiated by altered levels of 10 metabolites, 19 metabolic genes and six enzymes including 186 increased levels of 5NTC, NAMPT, BPNT1, PNPH and KCRU (Figures 4, Table S5 , S6), in 187 addition to decreased levels of 15 genes (Table S6) . Similarly, glycolysis and TCA cycle 188 metabolism ( Figure 4 ) was altered by increased levels of 7 metabolites, 33 genes and 13 189 proteins, including G6PD, PGM1, MAOM, IDHP, CISY and lower levels of F16P2 (Table S5) . 190
The combined action of these genes and proteins supports metabolic reprogramming towards 191 the pentose phosphate pathway (PPP) and TCA anaplerosis. NADPH metabolism ( Figure 4 ) 192 was activated via the PPP to provide more reducing potential for fatty acid synthesis and 193 increased levels of pentose sugars for nucleotide biosynthesis (Table S2 ). Higher levels of 194 GLYM, P5CS, P5CR1, P4HA1 and PRDX4 indicated increased collagen remodeling, a pathway DHCR7, involved in cholesterol biosynthesis, was higher in the ERneg tumors (Table S6) . 199
200
Identification of metabolic genes and proteins that were under-studied in breast cancer 201
Many of the differentially regulated proteins or genes in the network maps ( Figure 4 ) have been 202 studied before. Next, we asked which of these genes and proteins could serve as novel 203 therapeutic targets? To this end, we searched 30 million PubMed abstracts using key-word text-204 mining to rank all differentially regulated metabolic genes by their publication frequencies in 205 breast tumor biology (see Methods, Table S7 ). The resulting Table 2 gives the differential 206 expression for the top-50 most significant genes from the MetaCancer and the GEO meta-207 analysis study in relation to the publication record. This comparison yielded a range of metabolic 208 genes that are currently under-studied with less than five papers. Interestingly, over 2/3 of the 209 50-most significant metabolic genes are shown here to be severely understudied. Several of the 210 understudied genes are directly involved in critical metabolic pathways of tumor etiology, 211
including glucose metabolism (SORD), lipid biosynthesis (FAR1), cAMP signaling pathway 212 (PDE7A, ADCY6), and glutamate anaplerosis (ABAT, GLUD1). We pose that these under-213 studied genes should be further investigated in their role in breast tumor aggressiveness. To 214 check the clinical significance of these genes, we have used KMPlot 19 tool that estimates the 215 relapse free survival (RFS) using a standardized cohort of breast cancer gene expression 216 studies. We have found that 29 genes were positive associated with RFS and 11 genes 217 negatively associated with RFS in a meta-cohort of 1,809 patients ( Supplementary Table S15 ). 218
In the context of finding novel, drugable targets for ERneg breast tumors, we then analyzed 219 specifically the proteomics dataset with respect to finding the upregulated proteins that are 220 supported by the GEO meta-analysis, irrespective of the protein function or involvement in 221 metabolism. From a total of 1231 proteins, 295 proteins (24%) were differentially regulated in 222
MetaCancer with a raw p-value <0.05. 39 of these proteins were also found to be significantly 223 different in the GEO meta-analysis, of which 21 were up-regulated in ERneg tumors ( Figure 5A ). 224 Importantly, 10 of these proteins were found to be severely under-studied using our PubMed 225 text mining approach ( Figure 5B , Table S14 ), including CALML5, ACTR3, PADI2 and PFKP. 226
Among these 10 under-studied proteins, four proteins were encoded by metabolic genes, 227
including PFKP, GART, PLOD1 and ASS1. Although PFKP is a key regulatory enzyme in 228 glycolysis and gluconeogeneis pathways, only four PubMed abstracts were found targeting this 229 gene in breast cancer research. We propose to remove bias in study designs to not only study 230
heavily published genes such as CD44 and GSTP1 but also relevant new targets such as 231 PFKP, GART, PLOD1 and ASS1. 232 233
Discussion 234
Cancer metabolism is radically different from non-malignant cells. Breast cancers can be 235 grouped into different subtypes by presence of receptor genes, stages or grades. We here 236
focused on comparing ERneg and ERpos classes of breast cancer but did not extend this 237
analysis to further subtypes such as triple negative tumors using HER2 and PR status. When 238 designing the study, we queried the GEO database for finding a larger number of studies that 239 had ER-status reported to ensure to have a good base for meta-analysis of significantly 240 expressed metabolic genes. From the nine studies (plus MetaCancer) we downloaded from 241 GEO, only 5 had also information on HER2 status, reducing the power of gene expression 242 meta-analysis. Secondly, several of those studies had already small sample sizes, and if HER2 243 status was added, the meta-analysis would further lose statistical power. Similarly, our 244 proteomics data set consisted of only 14 triple-negative tumors, again compromising statistical 245 power for finding differences in metabolic genes. 246 Therefore, we focused on comparing ERneg and ERpos tumors for which we previously 247 showed stark differences between in central metabolism, altered ratios of glutamine/glutamate 248 (glutaminolysis) and beta-alanine accumulation 6 ; yet, an integrated analysis with prioritization 249 and a focus on candidate pathways and druggable targets was missing. Despite the established 250 importance of metabolism as hallmark of cancer, few other studies focused on the interplay of 251 genetic mutations and gene expression and actual metabolic phenotypes. Overall, we have 252 found that ERneg tumors show highly active biosynthesis of amino acids, lipids and nucleotides 253 and utilize substrate recycling as well as xenobiotic metabolism to support tumor growth. We 254 consciously constrained our approach to metabolic genes and gene products and here provide 255 the first integrated multi-omic analysis of ERneg versus ERpos tumors. We used solid statistical 256 footing to focus on interpretations of metabolic differences to find novel targets and give the first 257 example how in-depth text mining can be used to prioritize gene targets that have been largely 258 ignored in the literature. Yet, despite clear evidence from the data, not all metabolic enzymes 259 may be suitable as drug targets because they support critical metabolic pathways in cells 260 throughout the body. Hence, strong inhibition of such enzymes might lead to severe therapeutic 261 side-effects. Instead, knowledge about specific pathways might also be useful for targeting 262 regulatory and signaling pathways in metabolism that may have less toxicity in normal cells. Our 263 study results presented here support the idea that specific metabolic genes have gained less 264 attention than others, even if they act in the same pathway. For example, our analysis showed 265 that glutaminase is frequently reported in PubMed abstract in reference to breast cancer, 266
whereas the classic mitochondrial glutamate oxidation enzyme, GLUD1, has only been once 267 Concurrently, 5-deoxy-methylthioadenosine (MTA), a further purine salvage metabolite, was 280 also observed at higher levels in ER-negative tumors (Table S4 ). Aggressive tumors bypass 281 autophagy and apoptosis and hence, require more re-use of nucleotides for cell survival and cell 282 division. This process may therefore contribute to the cancer phenotype of cell survival. In 283 addition, cancer cells also activate de novo nucleotide biosynthesis. There are a range of drugs 284 targeting these metabolic pathways in chronic lymphocytic leukaemia, lung cancer and 285 pancreatic cancer 28 , but these drugs have not yet been repurposed to be tested against ER-286 negative tumors. Our analysis motivates and supports the initiation of such clinical trials of these 287 drugs for the management of ERneg breast tumors. 288 289
Microenvironment remodeling 290
Metabolites involved in collagen biosynthesis as well as collagen remodeling enzymes were 291 enriched in ER-negative tumors. Breast tumor cells increasingly rely on de novo biosynthesis of 292 proline for collagen metabolism 37 . Accordingly, we found increased levels of proline and trans-293 4-hydroxyproline as well as two enzymes involved in de novo biosynthesis of proline in ERneg 294 tumors, pyrroline-5-carboxylate reductase (PYCR) and P5C-synthase (ALDH18A1) ( Table S5) . it has been associated with breast cancer progression and metastatic spread 35 . As a scaffold of 300 tumor microenvironment, collagen changes in the microenvironment regulate ECM remodeling, 301 release signals and trigger a cascade of biological events, promote tumor invasion and 302 migration 14 . ECM proteins and ECM mediated signaling pathways may be promising drug 303 targets for breast cancer 23 . Along with the change of collagen genes, the expression levels 304 some chaperone and co-chaperone proteins, such as HSP90AA1, HSP90AB1, HSP90B1 and 305 CDC37, were higher in ERneg tumors, as well as YWHAQ, YWHAE ( Supplemental Table S9 ), 306 which involved in PI3K-AKT signaling pathway 40 . 307
Carbohydrate metabolism 309
The strongest effect supported by three omics levels (metabolites, proteins and genes) was 310 found for an increased PPP activity. PPP intermediates, ribose-5-phosphate and ribulose-5-311 phosphate, were increased in ERneg tumors, caused by an increase in the abundance of the 312 key oxidation enzymes, glucose-6-phosphate dehydrogenase (G6PD) and 6-phosphogluconate 313 dehydrogenase (PGD) and their encoding genes. Levels of transketolase, a key enzyme in the 314 non-oxidative branch of the pentose phosphate pathway, and its encoding gene TKT, were also 315 found increased in ERneg tumors. Further, gene expressions of phosphoglucomutase 1 316 (PGM1), ribose-5-phosphate isomerase (RPIA) and deoxyribose-phosphate aldolase (DERA) 317
were also upregulated in ERneg tumors (Table S5 , 7). The pentose phosphate pathway delivers 318 both NADPH and pentose phosphates required for cell division and tumor proliferation 26 . The 319 activation of this pathway supports tumor growth known for ERneg tumors. In comparison to the 320 clear differential regulation of the PPP, glycolytic enzymes showed less consistent regulation of 321 genes, proteins and metabolites when comparing ERneg to ERpos tumors. 322
323
Apart from metabolic changes in PPP, higher levels of three uncommon carbohydrates were 324 observed, including a two-fold increase in trehalose, maltose and maltotriose levels in ERneg 325 tumors (Table S4 and Figure 5 ). These oligosaccharides might be co-imported from blood along 326 with the well-known glucose uptake in tumors. This is the first report on these compounds in 327 relation to breast tumor metabolism; the maltose-degrading enzyme (GAA, LYAG) in the 328
MetaCancer study was found down-regulated (Table S5) while the corresponding gene was 329 found significantly down-regulated, consistent with other studies in the GEO meta-analysis 330 (Table S7 ). This significance in differential regulation of oligosaccharide metabolism in ERneg 331 tumors on all three omics levels suggests that further potentially this pathway could also be 332 important for future drug therapies. 333 334
Mitochondrial oxidation 335
We have observed increased levels of the metabolites nicotinamide and citric acid cycle (TCA) 336
intermediates citrate, alpha-ketoglutarate, malate, fumarate and succinate (Table S4) (Table S5) . Under hypoxic condition, attenuation of 339 electron transport chain in tumors is expected and NADH production in TCA can imbalance the 340 NAD+/NADH ratio. Targeting the NAD+ salvage pathway is a promising therapeutic option for 341 cancer patients 15 . Aggressive breast tumor shows an overexpression of hypoxia inducible factor 342 1 alpha (HIF-1) 4 . NAMPT also known as visfatin, the rate-limiting enzyme in the NAD salvage 343 pathway has been targeted by inhibitors such as FK866 21 and CHS-828 34 . This protein has also 344 been reported to be overexpressed in prostate cancer to promote tumor cell survival 42 and is 345 required for de novo lipogenesis in the tumor cells 5 . Over-expression of NAMPT in breast 346 cancer tissue is associated with poor survival 30 . Inhibiting NAMPT can also make the ERneg 347 breast cancer sensitive to additional chemotherapies as observed in vitro 2 . 348 349
Poorly studied metabolic genes 350
Transcriptomics analysis often reveals a long list of significant regulated genes, some of which 351 could be drivers for poor outcomes in subjects with ERneg tumors, while other genes might be 352 regulated downstream as bystanders. A focus on metabolic genes, combined with meta-353 analysis and multi-omics integration, is proposed here to remove bias in candidate gene 354 selections in the breast cancer research community. Gene expression meta-analysis yielded 34 355 significant metabolic genes that are underreported with fewer than five PubMed abstracts as 356 targets in breast cancer research, including NUDT12, FAR1, PDE7A, FAHD1, BLVRA, ITPK1, 357 SORD, HACD3, B4GALT5, CDS2, PPIP5K2, PDSS1, UGP2, GAMT, PLCH1, MAN2B2, 358 AHCYL1, SEPHS1, ATP5S, LCMT2, NT5DC2, AK4, CSAD, GLUD1, PDXK, ADCY6, COX6A1, 359 NME5, PIGH, COX4I1, COX6C, LIPG, LPIN1 and ABAT (Table 3 ). In addition, the combination 360 of proteomics and gene meta-analysis results revealed that 4 upregulated proteins encoded by 361 metabolic genes, PFKP, GART, PLOD1 and ASS1, were under-studied ( Figure 5B ). 362
363
For example, higher expression levels of gene encoding ATP-dependent 6-364 phosphofructokinase, platelet type (PFKP) were found to be statistically up-regulated in ERneg 365 tumors in eight out of ten GEO studies and specifically, was also found up-regulated in both the 366 proteomics and transcriptomics dataset of the MetaCancer cohort ( Figure 5B ). However, 367
PubMed text mining showed there were only four publications focused on PFKP in reference to 368 breast cancer. PFKP is a critical rate limiting enzyme in glycolysis, phosphorylating fructose-6-369 phosphate to fructose-1,6-bisphosphate and determining the rate of glycolytic flux versus flux 370 into the pentose phosphate pathway. Two further 6-phosphofructokinase isomers are existing in 371 humans, PFKM (muscle type) and PFKL (liver type) 41 . PFKM was not detected in our 372 proteomics dataset and not significantly different in transcriptomics dataset (raw p = 0.08), while 373 the gene expression of PFKL was upregulated in the MetaCancer ERneg breast tumor 374 transcriptomics dataset (raw p < 0.05). Therefore, targeting specific isoforms of 375 phosphofructokinase may be useful as potential target to deprive cancer cells from essential growth and metastasis through collagen-dependent extracellular matrix changes in TNBC 10 . We 386 therefore pose that PLOD isoforms may be interesting targets to study the relevance of 387 metabolism in the tumor microenvironment. 388
389
A third example is Argininosuccinate synthetase 1 (ASS1). ASS1 converts citrulline to arginine 390 and is a key enzyme in arginine biosynthesis that is critical for many functions, including nitric 391 oxide signaling or polyamine biosynthesis, as well as the liver urea cycle. In the MetaCancer 392 cohort, we found both ASS1 transcripts and the enzyme up-regulated in ERneg tumors ( Table  393 S5, S7), and the ASS1 substrate citrulline being decreased in the metabolomic results ( Table  394   S4 ). An inhibition should restrict arginine availability. Arginine starvation has been shown to 395 impair mitochondrial respiratory function in ASS1-deficient breast cancer cells 36 , suggesting that 396 arginine starvation therapy such as pegylated recombinant arginine deiminase (ADI-PEG20) 397 could be an option for patients with low ASS1 expression 43 . Dietary arginine restriction has also 398 been shown to reduce tumor growth in a xenograft model of ASS1-deficient breast cancer 9 . We 399 pose that such drugs with undergoing clinical trials could be repurposed for ERneg tumor 400 therapy. 401 402
Conclusions 403
We here show how multi-omics data can be utilized along with text mining to identify metabolic 404 genes and metabolic pathways that are under-studied in breast tumor research, specifically for 405
ERneg tumors that are known to have poor clinical outcomes. We see this approach as a 406 hypothesis-generating method, prioritizing the multitude of genes that are to be significant in 407 classic transcriptomics studies. We also showed that a meta-analysis of multiple studies refines 408 and strengthens candidate gene selections to study metabolic reprogramming. We propose 409 that such understudied, significant metabolic genes could be used as additional potential 410 therapy targets, especially if genes and proteins were found up-regulated in different breast 411 cancer studies, and if metabolite abundance support protein activities. 412
Material and Methods 414
MetaCancer cohort details: The study included 276 fresh frozen breast tumor biopsies and 415 126 FFPE tissues. They were collected for the tissue bank of the European FP7 MetaCancer 416 consortium at the Charité Hospital. The project was approved by the institutional review board of 417 the Charité Hospital (EA1/139/05). Further details about the cohort can be found in our previous 418 report (PMID:24125731). Biopsies were used for transcriptomics and metabolomics analysis 419 and FFPE tissues were used proteomics analysis. 420
MetaCancer metabolomics and proteomics data: GC-TOF MS data acquisition of the fresh 421 frozen tumor biopsies tissues was performed as previously published (22823888). FFPE tissues 422
were analyzed using a LTQ mass spectrometer for measuring proteins. Details are given in the 423
Supplementary Text S1. 424
Public breast tumor transcriptomics datasets : The MetaCancer transcriptomics dataset was 425 downloaded from the GEO omnibus database using the accession number GSE59198. Nine 426 other gene expression datasets were selected for which estrogen receptor status was available 427 in the GEO omnibus database. Details about these datasets are provided in the Table S1 . 428 429 Bioinformatics and statistical analysis : Metabolite enrichment analysis was performed 430 using the ChemRICH tool (29109515). Input file for the ChemRICH analysis is provided in the 431 Table S2 . Metabolic network mapping was performed using the MetaMapp software (22591066) 432 and the input file is provided in the Table S3 . MetaMapp network was visualized using the 433 Cytoscape software. Metabolites were linked to proteins using the KEGG and Expasy 434 databases. Links were visualized as an integrated network using the Cytoscape network 435 visualization software. Metabolites were linked to enzyme commission (EC) number first using 436 the KEGG database and EC number to protein mapping was obtained from the Expasy 437 database. Pathway over-representation analysis was conducted using the Reactome pathway 438 analysis tool (29145629, 28249561) because it provides the most comprehensive coverage of 439 metabolic pathway maps. Gene symbols and "breast cancer" were searched in the PubMed 440 database to get the count of abstracts for a gene and breast cancer. NCBI eutils web services 441 were used for running the searches for all the metabolic genes. All statistical analyses were 442 conducted using R. Mann-Whitney-Wilcoxon test was performed on both metabolomics and 443 proteomics datasets. GEO2R utility was used to analyze transcriptomics datasets. 
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